Neuroblastoma: Therapeutic strategies for a clinical enigma

Cancer Treatment Reviews

Volumn 36, Issue 4, 2010, Pages 307-317

  Modak, Shakeel ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Immunotherapy; Neuroblastoma; Therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; BEVACIZUMAB; CANCER VACCINE; CARBOPLATIN; CISPLATIN; CORTICOTROPIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FENRETINIDE; GUANETHIDINE; IFOSFAMIDE; IMMUNOGLOBULIN; IODINE 131; IRINOTECAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F8; MYC PROTEIN; PERIFOSINE; RECOMBINANT INTERLEUKIN 2; RETINOL; RITUXIMAB; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE; ZOLEDRONIC ACID;

ANAPHYLAXIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CHROMOSOME ABERRATION; CLINICAL TRIAL; DENDRITIC CELL; DIAGNOSTIC ACCURACY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; EVENT FREE SURVIVAL; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; HYPOTHYROIDISM; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; NEUROBLASTOMA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; RADIATION DOSE; REVIEW; SIALOADENITIS; T LYMPHOCYTE; THROMBOCYTOPENIA; TUMOR LOCALIZATION;

3-IODOBENZYLGUANIDINE; ADOPTIVE TRANSFER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY; NEOPLASM STAGING; NEUROBLASTOMA;

EID: 77953024995     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.02.006     Document Type: Review

References (166)

1. Yamamoto K., Hayashi Y., Hanada R., et al. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture. Jpn J Clin Oncol 1995, 13:2033-2038.
2. Woods W.G., Gao R.N., Shuster J.J., et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002, 346:1041-1046.
3. Franks L.M., Bollen A., Seeger R.C., Stram D.O., Matthay K.K. Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer 1997, 79:2028-2035.
4. Kushner B.H., Kramer K., LaQuaglia M.P., Modak S., Cheung N.K. Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience. Med Pediatr Oncol 2003, 41:508-515.
5. Schwab M., Alitalo K., Klempnauer K.-H., et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and neuroblastoma tumor. Nature 1983, 305:245-248.
6. Shimada H., Stram D.O., Chatten J., et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 1995, 87:1470-1476.
7. Brodeur G., Pritchard J., Berthold F., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 1993, 11:1466-1477.
8. Monclair T., Brodeur G.M., Ambros P.F., et al. The international neuroblastoma risk group (INRG) staging system: an INRG task force report. J Clin Oncol 2009, 27:298-303.
9. Cohn S.L., Pearson A.D., London W.B., et al. The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J Clin Oncol 2009, 27:289-297.
10. Brodeur GM, Maris JM. Neuroblastoma. Princ Pract Pediatr Oncol, 2006.
11. Kushner B.H., Cheung N.K., LaQuaglia M.P., et al. International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review. J Clin Oncol 1996, 14:2174-2180.
12. Hero B., Simon T., Spitz R., et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol 2008, 26:1504-1510.
13. Cheung N.K.V., Kushner B.H., LaQuaglia M.P., et al. Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biologic markers. Eur J Cancer 1997, 33:2117-2121.
14. Kushner B.H., Cheung N.K., LaQuaglia M.P., et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol 1996, 14:373-381.
15. Bagatell R., Rumcheva P., London W.B., et al. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol 2005, 23:8819-8827.
16. George R.E., Li S., Medeiros-Nancarrow C., et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 2006, 24:2891-2896.
17. Berthold F., Boos J., Burdach S., et al. Myeloablative megatherapy with autologous 28 stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005, 6:649-658.
18. Matthay K.K., Villablanca J.G., Seeger R.C., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's cancer group. N Engl J Med 1999, 341:1165-1173.
19. Laverdiere C., Cheung N.K., Kushner B.H., et al. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 2005, 45:324-332.
20. De Bernardi B., Conte M., Mancini A., et al. Localized resectable neuroblastoma: results of the second study of the Italian cooperative group for neuroblastoma. J Clin Oncol 1995, 13:884-893.
21. Modak S., Kushner B.H., LaQuaglia M.P., Kramer K., Cheung N.K. Management and outcome of stage 3 neuroblastoma. Eur J Cancer 2009, 45:90-98.
22. Matthay K.K., Sather H.N., Seeger R.C., Haase G.M., Denman Hammond G. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 1989, 7:236-244.
23. Perez C.A., Matthay K.K., Atkinson J.B., et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol 2000, 18:18-26.
24. Maris J.M., Hogarty M.D., Bagatell R., Cohn S.L. Neuroblastoma. Lancet 2007, 369:2106-2120.
25. Matthay K.K., Perez C., Seeger R.C., et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a children's cancer group study. J Clin Oncol 1998, 16:1256-1264.
26. Park J.R., Villablanca J.G., London W.B., et al. Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the children's oncology group. Pediatr Blood Cancer 2009, 52:44-50.
27. Park JE, London W, Maris JM, et al. Prognostic markers for stage 3 neuroblastoma (NB): a report from the international neuroblastoma risk group (INRG) project. Proc ASCO, 2008.
28. Attiyeh E.F., London W.B., Mosse Y.P., et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005, 353:2243-2253.
29. Bown N., Cotterill S., Lastowska M., et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999, 340:1954-1961.
30. De Bernardi B., Balwierz W., Bejent J., et al. Epidural compression in neuroblastoma: diagnostic and therapeutic aspects. Cancer Lett 2005, 228:283-299.
31. Sandberg D.I., Bilsky M.H., Kushner B.H., et al. Treatment of spinal involvement in neuroblastoma patients. Pediatr Neurosurg 2003, 39:291-298.
32. Pranzatelli M.R., Tate E.D., Travelstead A.L., et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006, 28:585-593.
33. Pranzatelli M.R., Tate E.D., Travelstead A.L., Longee D. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome. Pediatrics 2005, 115:e115-e119.
34. Bagatell R., Beck-Popovic M., London W.B., et al. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the international neuroblastoma risk group database. J Clin Oncol 2009, 27:365-370.
35. Evans A.E., Baum E., Chard R. Do infants with stage IV-S neuroblastoma need treatment?. Arch Disease Child 1981, 56:271-274.
36. Katzenstein H.M., Bowman L.C., Brodeur G.M., et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience - a pediatric oncology group study. J Clin Oncol 1998, 16:2007-2017.
37. Mora J., Cheung N.K., Kushner B.H., et al. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. J Mol Diagn 2000, 2:37-46.
38. Spitz R., Hero B., Ernestus K., Berthold F. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin Cancer Res 2003, 9:52-58.
39. Schmidt M.L., Lal A., Seeger R.C., et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a children's cancer group study. J Clin Oncol 2005, 23:6474-6480.
40. George R.E., London W.B., Cohn S.L., et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a pediatric oncology group study. J Clin Oncol 2005, 23:6466-6473.
41. Pearson A.D., Pinkerton C.R., Lewis I.J., Imeson J., Ellershaw C., Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 2008, 9:247-256.
42. De Bernardi B., Nicolas B., Boni L., et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian co-operative group for neuroblastoma. J Clin Oncol 2003, 21:1592-1601.
43. Cheung N.K., Heller G. Chemotherapy dose intensity correlates strongly with response, median survival and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991, 9:1050-1058.
44. Cheung N.K., Kushner B.H., LaQuaglia M., et al. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol 2001, 36:227-230.
45. Kushner B.H., Kramer K., LaQuaglia M.P., Modak S., Yataghene K., Cheung N.K. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol 2004, 22:4888-4892.
46. Shamberger R.C., Allarde-Segundo A., Kozakewich H.P., Grier H.E. Surgical management of stage III and IV neuroblastoma: resection before or after chemotherapy?. J Pediatr Surg 1991, 26:1113-1117. [discussion 7-8].
47. Wolden S.L., Gollamudi S.V., Kushner B.H., et al. Local control with multimodality therapy for stage 4 neuroblastoma. Int J Radiat Oncol Biol Phys 2000, 46:969-974.
48. La Quaglia M.P. Surgical management of neuroblastoma. Semin Pediatr Surg 2001, 10:132-139.
49. Wolden S.L., Barker C.A., Kushner B.H., et al. Brain-sparing radiotherapy for neuroblastoma skull metastases. Pediatr Blood Cancer 2008, 50:1163-1168.
50. Kushner B.H., Wolden S., LaQuaglia M.P., et al. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol 2001, 19:2821-2828.
51. Kletzel M., Katzenstein H.M., Haut P.R., et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago pilot II study. J Clin Oncol 2002, 20:2284-2292.
52. Klingebiel T., Bader P., Bares R., et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 1998, 34:1398-1402.
53. Matthay K.K., Seeger R.C., Reynolds C.P., et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the childrens cancer group. J Clin Oncol 1994, 12:2382-2389.
54. Kushner B.H., Kramer K., Modak S., et al. Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system. Bone Marrow Transplant 2006, 37:271-276.
55. Modak S., Cheung N.K. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 2007, 25:67-77.
56. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 2001, 491:369-402.
57. Kushner B.H., Cheung I.Y., Kramer K., Modak S., Cheung N.K. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy. Pediatr Blood Cancer 2007, 48:430-434.
58. Kushner B.H., Kramer K., Modak S., Cheung N.K. Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma. Clin Cancer Res 2004, 10:84-87.
59. Cheung N.K., Kushner B.H., Cheung I.Y., et al. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 1998, 16:3053-3060.
60. Gilman A.L., Ozkaynak M.F., Matthay K.K., et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the children's oncology group. J Clin Oncol 2009, 27:85-91.
61. Cheung N.K., Saarinen U.M., Neely J.E., Landmeier B., Donovan D., Coccia P.F. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 1985, 45:2642-2649.
62. Xu H., Hu J., Cheung N.K. Induction of tumor cell death by anti-GD2 monoclonal antibodies: requirement of antibody Fc and a long residence time (slow k off). J Clin Oncol ASCO Annu Meet Proc 2007, 25:13507.
63. Munn D.H., Cheung N.K. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity (ADCC) against human melanoma. Cancer Res 1987, 47:6600-6605.
64. Munn D.H., Cheung N.K. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release 31 assays. J Exp Med 1989, 170:511-526.
65. Kushner B.H., Cheung N.K. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 1989, 73:1936-1941.
66. Kushner B.H., Cheung N.K. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity. Blood 1992, 79:1484-1490.
67. Hong F., Yan J., Baran J.T., et al. Mechanism by which orally administered beta-1, 3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol 2004, 173:797-806.
68. Kushner B., Kramer K., Modak S., Cheung N.K. Anti-GD2 monoclonal antibody 3F8 plus granulocyte macrophage colony stimulating factor for primary refractory neuroblastoma in bone marrow. Proc ASCO 2007, 25:9502.
69. Gillies S.D., Lo K.-M., Wesolowski J. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods 1989, 125:191-202.
70. Barker E., Mueller B.M., Handgretinger R., Herter M., Yu A.L., Reisfeld R.A. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 1991, 51:144-149.
71. Barker E., Reisfeld R.A. A mechanism for neutrophil-mediated lysis of human neuroblastoma cells. Cancer Res 1993, 53:362-367.
72. Mueller B.M., Romerdahl C.A., Gillies S.D., Reisfeld R.A. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 1990, 144:1382-1386.
73. Simon T., Hero B., Faldum A., et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 2004, 22:3549-3557.
74. Yu A, Gilman A, Ozkaynak M, et al. A phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: Children's Oncology Group (COG) study ANBL0032. Proc ASCO, 2009:abs 10067z.
75. Thiele C.J., Reynolds C.P., Israel M.A. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985, 313:404-406.
76. Linney E. Retinoic acid receptors: transcription factors modulating gene regulation, development, and differentiation. Curr Top Dev Biol 1992, 27:309-350.
77. Kohler J.A., Imeson J., Ellershaw C., Lie S.O. A randomized trial of 13-cis retinoic acid in children with advanced neuroblastoma after high-dose therapy. Br J Cancer 2000, 83:1124-1127.
78. Villablanca J.G., Krailo M.D., Ames M.M., Reid J.M., Reaman G.H., Reynolds C.P. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the children's oncology group (CCG 09709). J Clin Oncol 2006, 24:3423-3430.
79. Kramer K., Kushner B., Heller G., Cheung N.K. Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-Kettering cancer center experience and a literature review. Cancer 2001, 91:1510-1519.
80. Matthay K.K., Brisse H., Couanet D., et al. Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer 2003, 98:155-165.
81. Kramer K, Kushner B, Modak S, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol 2010 (in press).
82. Kramer K., Humm J.L., Souweidane M.M., et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol 2007, 25:5465-5470.
83. Lau L., Tai D., Weitzman S., Grant R., Baruchel S., Malkin D. Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol 2004, 26:227-232.
84. Kushner B., Kramer K., Modak S., Cheung N.K. Sensitivity of surveillance studies for detecting aysmtomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol 2009, 27:1041-1046.
85. Langler A., Christaras A., Abshagen K., Krauth K., Hero B., Berthold F. Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study. Klin Padiatr 2002, 214:153-156.
86. Garaventa A., Luksch R., Biasotti S., et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer 2003, 98:2488-2494.
87. Kramer K., Kushner B.H., Cheung N.K. Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis. J Pediatr Hematol Oncol 2003, 25:601-605.
88. Wagner L.M., Crews K.R., Iacono L.C., et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 2004, 10:840-848.
89. Vassal G., Giammarile F., Brooks M., et al. A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Societe Francaise d'Oncologie Pediatrique (SFOP) and the United Kingdom children cancer study group (UKCCSG). Eur J Cancer 2008, 44:2453-2460.
90. Kushner B.H., Kramer K., Modak S., Cheung N.K. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 2006, 24:5271-5276.
91. Fox E., Maris J.M., Widemann B.C., et al. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res 2008, 14:1111-1115.
92. Kushner B.H., Kramer K., Cheung N.K. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 2001, 19:4189-4194.
93. Cheung N.K., Modak S. Oral (1→3),(1→4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res 2002, 8:1217-1223.
94. Cheung N.K., Modak S., Vickers A., Knuckles B. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother 2002, 51:557-564.
95. Modak S., Koehne G., Vickers A., O'Reilly R.J., Cheung N.K. Rituximab therapy of lymphoma is enhanced by orally administered (1→3),(1→4)-d-beta-glucan. Leuk Res 2005, 29:679-683.
96. Modak S, Kushner B, Kramer K, Vickers A, Cheung NK. Combination of anti-GD2 antibody 3F8 and barley-derived (1→3), 1→4) →-D-glucan: phase I study in patients with resistant neuroblastoma advances in neuroblastoma research. Proc ANR 2006:abs 326.
97. Gillies S.D., Reilly E.B., Lo K.M., Reisfeld R.A. Antibody-targeted interleukin-2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA 1992, 89:1428-1432.
98. Hank J.A., Surfus J.E., Gan J., et al. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). Clin Cancer Res 1996, 2:1951-1959.
99. Pancook J.D., Becker J.C., Gillies S.D., Reisfeld R.A. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunol Immunother 1996, 42:88-92.
100. Osenga K, Hank J, Albertini MR, et al. A phase I trial of immunocytokine HU14.18-IL12 in children with recurrent or refractory neuroblastoma and other GD2 positive malignancies: a study of the children's oncology group. Proc ISBTC, 2004:50.
101. Shusterman S, London W, Gillies SA, et al. Anti-neuroblastoma activity of hu14.18-IL2 against minimal residual disease in a children's oncology group phase II study. J Clin Oncol 2008;26 Suppl:Abs 3002.
102. Yeh S.D., Larson S.M., Burch L., et al. Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine (MIBG) and standard diagnostic modalities. J Nucl Med 1991, 32:769-776.
103. Cheung NK, Pentlow K, Graham MC, Yeh SDJ, Finn RD, Larson SM. Radioimmunotherapy of human neuroblastoma using monoclonal antibody 3F8. In: Fifth international radiopharmaceutical dosimetry symposium. Oak Ridge, Tennessee: Oak Ridge Associated Universities; 1992. p. 95-112.
104. Modak S., Cheung N.K. Antibody-based targeted radiation to pediatric tumors. J Nucl Med 2005, 46(Suppl. 1):157S-163S.
105. Modak S, Chung J, Cheung NK. Targeting of vascular endothelial growth factor (VEGF) synergizes with 131I-3F8 in radioimmunotherapy of human neuroblastoma (abs accepted for presentation at AACR 2006). Proc AACR 2006; p. 135-6.
106. Modak S, Cheung NK, Abramson SJ, Price AP. Lack of early bevacizumab-related skeletal radiographic changes in children with neuroblastoma. Pediatr Blood Cancer, 2008.
107. Meli M.L., Carrel F., Waibel R., et al. Anti-neuroblastoma antibody chCE7 binds to an isoform of L1-CAM present in renal carcinoma cells. Int J Cancer 1999, 83:401-408.
108. Shurin G.V., Shurin M.R., Bykovskaia S., Shogan J., Lotze M.T., Barksdale E.M. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 2001, 61:363-369.
109. Wolfl M., Batten W.Y., Posovszky C., Bernhard H., Berthold F. Gangliosides inhibit the development from monocytes to dendritic cells. Clin Exp Immunol 2002, 130:441-448.
110. Valteau-Couanet D., Leboulaire C., Maincent K., et al. Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Blood 2002, 100:2554-2561.
111. Morandi F., Chiesa S., Bocca P., et al. Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications. Neoplasia 2006, 8:833-842.
112. Geiger J.D., Hutchinson R.J., Hohenkirk L.F., et al. Vaccination of pediatric solid 34 tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001, 61:8513-8519.
113. Caruso D.A., Orme L.M., Amor G.M., et al. Results of a phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with stage 4 neuroblastoma. Cancer 2005, 103:1280-1291.
114. Castriconi R., Dondero A., Augugliaro R., et al. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci USA 2004, 101:12640-12645.
115. Castriconi R., Dondero A., Cilli M., et al. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Cancer Immunol Immunother 2007, 56:1733-1742.
116. Castriconi R., Dondero A., Corrias M.V., et al. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res 2004, 64:9180-9184.
117. Venstrom J., Zheng J., Noor N., et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Can Res 2009, 15:7330-7334.
118. Pule M.A., Savoldo B., Myers G.D., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008, 14:1264-1270.
119. Park J.R., Digiusto D.L., Slovak M., et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007, 15:825-833.
120. Rousseau R.F., Haight A.E., Hirschmann-Jax C., et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003, 101:1718-1726.
121. Russell H.V., Strother D., Mei Z., et al. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother 2007, 30:227-233.
122. Russell H.V., Strother D., Mei Z., et al. A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother 2008, 31:812-819.
123. Zeytin H., Tripathi P.K., Bhattacharya-Chatterjee M., Foon K.A., Chatterjee S.K. DNA vaccine based on the structure of an anti idiotype antibody mimicking the GD2 ganglioside. Proc Am Assoc Cancer Res 1997, 38:399.
124. Yu A. Promising results of a pilot trial of a GD2 directed anti-idiotypic antibody as a vaccine for high risk neuroblastoma. Proc ANR Meet (abs), 2004.
125. Ragupathi G., Livingston P., Hood C., et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-2. Clin Canc Res 2003, 9:5214-5220.
126. Livingston P.O., Adluri S., Helling F. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccines 1994, 12:1275-1280.
127. DuBois S.G., Messina J., Maris J.M., et al. Hematologic toxicity of high-dose iodine-35 131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 2004, 22:2452-2460.
128. Matthay KK, Huberty J, Hawkins RA, et al. 131-I-MIBG double infusion with autologous stem cell transplant (ASCT) for neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. In: Advances in neuroblastoma research: eleventh conference. J Clin Oncol 2009;27:1020-5.
129. Corbett R., Olliff J., Fairley N., et al. A prospective comparison between magnetic resonance imaging, meta-iodobenzylguanidine scintigraphy and marrow histology/cytology in neuroblastoma. Eur J Cancer 1991, 27:1560-1564.
130. Yanik G.A., Levine J.E., Matthay K.K., et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002, 20:2142-2149.
131. Miano M., Garaventa A., Pizzitola M.R., et al. Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplant 2001, 27:571-574.
132. Fitzgerald P.A., Goldsby R.E., Huberty J.P., et al. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci 2006, 1073:465-490.
133. Osajima-Hakomori Y., Miyake I., Ohira M., Nakagawara A., Nakagawa A., Sakai R. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 2005, 167:213-222.
134. Lamant L., Pulford K., Bischof D., et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 2000, 156:1711-1721.
135. Mosse Y.P., Laudenslager M., Longo L., et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930-935.
136. Caren H., Abel F., Kogner P., Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 2008, 416:153-159.
137. George R.E., Sanda T., Hanna M., et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455:975-978.
138. Scala S., Wosikowski K., Giannakakou P., et al. Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity. Cancer Res 1996, 56:3737-3742.
139. Schramm A., Schulte J.H., Astrahantseff K., et al. Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer Lett 2005, 228:143-153.
140. Belkov V.M., Krynetski E.Y., Schuetz J.D., et al. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood 1999, 93:1643-1650.
141. Sartelet H., Oligny L.L., Vassal G. AKT pathway in neuroblastoma and its therapeutic implication. Expert Rev Anticancer Ther 2008, 8:757-769.
142. Coulter D.W., Blatt J., D'Ercole A.J., Moats-Staats B.M. IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth. Anticancer Res 2008, 28:1509-1516.
143. Kolb E.A., Gorlick R., Houghton P.J., et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50:1190-1197. 36.
144. Tweddle D.A., Pearson A.D., Haber M., et al. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 2003, 197:93-98.
145. Tweddle D.A., Malcolm A.J., Cole M., Pearson A.D., Lunec J. P53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. Am J Pathol 2001, 158:2067-2077.
146. Chesler L., Goldenberg D.D., Collins R., et al. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia 2008, 10:1268-1274.
147. Tweddle D.A., Malcolm A.J., Bown N., Pearson A.D., Lunec J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 2001, 61:8-13.
148. Carr J., Bell E., Pearson A.D., et al. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res 2006, 66:2138-2145.
149. Yu Q. Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy. Drug Resist Updat 2006, 9:19-25.
150. Shankar S.L., Krupski M., Parashar B., et al. UCN-01 alters phosphorylation of Akt and GSK3beta and induces apoptosis in six independent human neuroblastoma cell lines. J Neurochem 2004, 90:702-711.
151. Condorelli F., Gnemmi I., Vallario A., Genazzani A.A., Canonico P.L. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 2008, 153:657-668.
152. Coffey D.C., Kutko M.C., Glick R.D., et al. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 2001, 61:3591-3594.
153. Coffey D.C., Kutko M.C., Glick R.D., et al. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol 2000, 35:577-581.
154. Eggert A., Ikegaki N., Kwiatkowski J., Zhao H., Brodeur G.M., Himelstein B.P. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 2000, 6:1900-1908.
155. Ribatti D., Raffaghello L., Marimpietri D., et al. Fenretinide as an anti-angiogenic agent in neuroblastoma. Cancer Lett 2003, 197:181-184.
156. Kaicker S., McCrudden K.W., Beck L., et al. Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma. Int J Oncol 2003, 23:1651-1655.
157. Kim E.S., Serur A., Huang J., et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 2002, 99:11399-11404.
158. Bender J.L., Adamson P.C., Reid J.M., et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a children's oncology group study. J Clin Oncol 2008, 26:399-405.
159. Peng H., Sohara Y., Moats R.A., et al. The activity of zoledronic acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Cancer Res 2007, 67:9346-9355.
160. Opel D., Poremba C., Simon T., Debatin K.M., Fulda S. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 2007, 67:735-745.
161. LoPiccolo J., Blumenthal G.M., Bernstein W.B., Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008, 11:32-50.
162. Modak S., Kramer K., Gultekin S.H., Guo H.F., Cheung N.K. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res 2001, 61:4048-4054.
163. Kramer K, Smith-Jones P, Humm J, et al. Therapy of central nervous system and leptomeningeal cancers with intra-Ommaya radioiodine labeled 3F8: preliminary results of a phase II study. Proc AACR, 2007:LB-L7.
164. Valteau-Couanet D., Michon J., Boneu A., et al. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French society of pediatric oncology (SFOP) protocol. J Clin Oncol 2005, 23:532-540.
165. Hobbie W.L., Moshang T., Carlson C.A., et al. Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr Blood Cancer 2008, 51:679-683.
166. Brodeur G.M., Pritchard J., Berthold F., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993, 11:1466-1477.